EGFR Signaling in Colorectal Cancer Metastasis: Molecular Mechanisms and Targeted Therapeutic Strategies
Open Access
- 18 November 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10346
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, with metastatic colorectal cancer (mCRC) accounting for most CRC-associated deaths. Despite advances in systemic therapy, mCRC remains associated with poor prognosis because of its molecular heterogeneity, metastatic potential, and the emergence of therapeutic resistance. Improved understanding of the molecular landscape of mCRC has enabled biomarker-driven treatment strategies that have advanced precision oncology. Among the key signaling pathways involved in mCRC, the epidermal growth factor receptor (EGFR) pathway plays a central role in tumor progression and metastasis. EGFR activation triggers the RAS-RAF-MEK-ERK (rat sarcoma-rapidly accelerated fibrosarcoma-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase) and PI3K-AKT-mTOR (phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin) signaling cascades, promoting cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Genetic alterations involving KRAS (kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma rat sarcoma viral oncogene homolog), BRAF (B-Raf proto-oncogene, serine/threonine kinase), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), HER2 (human epidermal growth factor receptor 2), and PTEN (phosphatase and tensin homolog) frequently dysregulate these pathways and serve as predictive biomarkers for targeted therapy. Anti-EGFR monoclonal antibodies have transformed the treatment landscape of mCRC. However, their clinical benefit is frequently limited by intrinsic and acquired resistance mechanisms driven by molecular alterations, pathway redundancy, compensatory signaling, and tumor heterogeneity. This review examines the role of EGFR signaling in CRC metastasis, the molecular alterations affecting EGFR-associated pathways, and the evolving landscape of EGFR-directed and pathway-focused targeted therapies in mCRC.Keywords
This publication has 173 references indexed in Scilit:
- Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal CancerJAMA Oncology, 2023
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal CancerJAMA, 2023
- Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal CancerJAMA Oncology, 2021
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal CancerJAMA Oncology, 2019
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and IrinotecanJAMA Oncology, 2019
- Cancer DNA in the CirculationJAMA, 2017
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal CancerJAMA, 2017
- Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients WithRASWild-Type Advanced Colorectal CancerJAMA Oncology, 2016
- Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinomaCancer, 2001